LuMend's Breakthrough Break Out
Executive Summary
For many device companies and their investors, drug-eluting stents have come to represent a kind of technological end-game, a device so successful at solving an important unmet need that all future opportunities lie elsewhere. But, in fact, there are still many important unsolved problems in interventional cardiology, not the least of which is chronic total occlusions, lesions so thick and dense that blood can't flow through the artery. That's the problem LuMend has set out to solve and it has the first US-approved device on the market. And while some question the company's timing, LuMend officials argue they couldn't be better timed, since their device and drug-eluting stents go hand in hand.
You may also be interested in...
Avinger: Finally, Seeing Through Total Occlusions, But Will Clinical Value Generate Economic Return?
Noted physician/entrepreneur John Simpson is back. His latest company, Avinger, has finally achieved his long-sought goal: combining imaging and therapeutics in catheter technology for crossing CTOs. Will clinical innovation be enough to reward Avinger in an increasingly economically focused medtech world?
FlowCardia: Playing it Safe in Total Occlusions
Chronic total occlusions remain one of the most significant challenges and opportunities facing interventional cardiologists and radiologists. FlowCardia is looking to succeed where other device companies have failed by emphasizing safety and simplicity.
FlowCardia: Playing it Safe in Total Occlusions
Chronic total occlusions remain one of the most significant challenges and opportunities facing interventional cardiologists and radiologists. FlowCardia is looking to succeed where other device companies have failed by emphasizing safety and simplicity.